Log in to save to my catalogue

Head‐to‐head evaluation of leading blood tests for amyloid pathology

Head‐to‐head evaluation of leading blood tests for amyloid pathology

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713747

Head‐to‐head evaluation of leading blood tests for amyloid pathology

Publication information

Publisher

Hoboken: John Wiley and Sons Inc

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Background
Blood tests that accurately determine the presence of amyloid pathology are critically needed. Compared to amyloid PET and CSF tests, blood tests are less expensive, less invasive, more accessible, and highly scalable. The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium evaluated the accuracies of leading...

Alternative Titles

Full title

Head‐to‐head evaluation of leading blood tests for amyloid pathology

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713747

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713747

Other Identifiers

ISSN

1552-5260

E-ISSN

1552-5279

DOI

10.1002/alz.095506

How to access this item